<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00989872</url>
  </required_header>
  <id_info>
    <org_study_id>EDP-322-007-001</org_study_id>
    <nct_id>NCT00989872</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-Controlled, Ascending Single-Dose Safety, Tolerability, and Pharmacokinetics Study of EDP-322 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enanta Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Enanta Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      This was a randomized, double-blind, placebo-controlled, ascending single dose safety,&#xD;
      tolerability, and pharmacokinetic study of orally administered EDP-322. This study was&#xD;
      conducted at a single site. EDP-322 has a benefit to risk profile that supports testing in&#xD;
      target patient populations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The study objectives included determining the safety, tolerability and pharmacokinetics of single oral doses of EDP-322 in healthy adult volunteers</measure>
  </primary_outcome>
  <enrollment type="Actual">67</enrollment>
  <condition>Skin and Soft Tissue Infections</condition>
  <condition>Methicillin-resistant Staphylococcus Aureus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-322</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult males or females [if documentation existed that they were surgically&#xD;
             sterilized].&#xD;
&#xD;
          -  Were in good general health as determined by medical history, physical exam and&#xD;
             clinical laboratory tests, and without evidence of clinically significant abnormality,&#xD;
             in the opinion of the Investigator and Medical Monitor.&#xD;
&#xD;
          -  The resting 12-lead ECG obtained at Screening shows no clinically significant&#xD;
             abnormality and a QTc (Bazett's correction) &lt;450 msec.&#xD;
&#xD;
          -  Weight less than 132 pounds (60kg) with BMI between 18-32 kg/m3, inclusive.&#xD;
&#xD;
          -  Subject has read, understood, and signed the written informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of chronic or recurrent renal, hepatic, pulmonary, allergic, cardiovascular,&#xD;
             gastrointestinal, endocrine, central nervous system, hematologic or metabolic&#xD;
             diseases, or immunologic, emotional and/or psychiatric disturbances.&#xD;
&#xD;
          -  History of gastric surgery, vagotomy, bowel resection, or any surgical procedure that&#xD;
             might interfere with gastrointestinal motility, pH, or absorption.&#xD;
&#xD;
          -  Any abnormal or screening clinical lab test results...&#xD;
&#xD;
          -  Medication Related exclusions...&#xD;
&#xD;
          -  Lifestyle related...&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas L Hunt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PPD Phase I Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Phase I Unit</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>October 5, 2009</study_first_submitted>
  <study_first_submitted_qc>October 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2009</study_first_posted>
  <last_update_submitted>October 5, 2009</last_update_submitted>
  <last_update_submitted_qc>October 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Maria T. Madison, Dir. Clinical Operations</name_title>
    <organization>Enanta Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Macrolides</keyword>
  <keyword>Antibiotics</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Phase I</keyword>
  <keyword>MRSA/SSTI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soft Tissue Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

